Illumina stock rises after acquiring Fluent Biosciences, with potential for significant revenue and earnings growth

From Nasdaq: 2024-07-14 22:55:14

The rise in Illumina stock (ILMN) can be attributed to its acquisition of Fluent Biosciences to enhance its offerings. Despite a 70% drop from $370 in early 2021 to $115 now, forecasts show a potential 25% increase. Revenue grew from $3.2 billion in 2020 to $4.5 billion in 2023 due to increased demand for gene sequencing. Bottom-line growth is expected to be over 5x by 2025.

With a 6% rise in stock on July 10, Illumina outperformed Mettler-Toledo stock, primarily due to the acquisition of Fluent Biosciences. Despite a decline after the Grail acquisition, Illumina’s valuation is expected to improve, with analysts predicting a 25% upside. Revenue has increased to $4.5 billion in 2023, driven by gene sequencing demand and population genomics testing.

Investors are optimistic about the potential growth of Illumina stock as the company expands its single-cell analysis and multiomics offerings through acquisition. Despite setbacks following the Grail acquisition, the company is expected to see significant earnings growth in the coming years. With the Fluent Biosciences acquisition, Illumina is positioned to capture more market share in single-cell analysis.



Read more at Nasdaq: What’s Happening With Illumina Stock?